Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo. Weight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) are Prescription-Only Medicines in the UK, which means a qualified prescriber must assess your health before any supply is legal. There is no legitimate route to these treatments without a clinical consultation. That is not a technicality — it is the foundation of safe prescribing, and it matters more than it might first appear. If you have come across sellers offering these medicines weight loss injections without that step, the MHRA has made clear this is a serious safety risk. A real consultation, carried out by a GPhC-registered Independent Prescriber who reads your answers personally, is the starting point for anyone considering this treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Human Medicines Regulations 2012 classify Mounjaro and Wegovy as Prescription-Only Medicines precisely because their effects go beyond what a patient can safely self-assess. Both carry a Black Triangle (▼) designation, meaning the MHRA requires additional post-market surveillance while real-world safety data continues to build. The NHS guidance on tirzepatide sets out who these medicines are intended for, what they interact with, and when they should not be used at all, information a prescriber weighs before writing a prescription, not after.
The MHRA has been explicit on this point. Its public guidance on GLP-1 medicines for weight loss states these treatments are not assessed for quick or cosmetic weight loss and require proper clinical oversight. That is not bureaucracy for its own sake. Tirzepatide, for instance, is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, conditions a prescriber checks for at consultation. Acute pancreatitis is a known infrequent but serious risk; a prescriber considers whether someone's history puts them at higher risk before the first pen is ever issued.
Suitability also depends on what else someone is taking. Women using oral contraceptives starting tirzepatide need an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because gastric slowing can reduce pill absorption. A prescriber explains this. A social-media seller does not.
This is the part worth understanding clearly. The MHRA has seized approximately 20 million doses of illegally traded weight loss medicines, worth around £45 million, and in October 2025 raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens, in Northampton. Earlier enforcement actions found fake pens containing insulin rather than the labelled medicine, leading to hospitalisations. You can report suspect sellers directly through the MHRA Yellow Card scheme.
A common misconception is that these cases involve obviously dodgy websites, the kind no sensible person would use. In practice, many illegal supplies have come through social media, messaging apps, and listings that look credible enough. The absence of a consultation requirement is itself the red flag. Any seller willing to dispatch a Prescription-Only Medicine without first having a prescriber assess you has already demonstrated that their process is not built around your safety.
You can verify whether an online pharmacy is legitimately registered at the GPhC pharmacy register. If a pharmacy is not listed there, walk away. If it is listed but still does not require a clinical assessment before dispensing a POM, that is also a serious concern worth reporting.
People sometimes imagine a consultation means a long GP appointment, a referral letter, and months of waiting. That is one route (the NHS route) and it comes with eligibility thresholds and waiting lists that not everyone will meet or want to navigate. A private online consultation through a regulated pharmacy works differently. You complete a structured health questionnaire covering your BMI, medical history, current medicines, and relevant conditions. A GPhC-registered Independent Prescriber reads it the same day. A real clinician considers your answers, not an algorithm. If treatment is clinically suitable, a prescription is written. If it is not, you are told why.
The consultation also confirms which injection is the better fit. Mounjaro and Wegovy work differently: tirzepatide activates two gut-hormone receptors (GIP and GLP-1), while semaglutide targets one. Trial evidence (including the SURMOUNT-5 head-to-head study published in the New England Journal of Medicine in 2025) found tirzepatide produced greater average weight reduction over 72 weeks. Part of that clinical picture includes understanding your surgical history, and if you have had your gallbladder removed you can read about how that affects your suitability for weight loss injections before speaking to a prescriber. You can read more about how to access weight loss injections through a regulated route if you would like a clearer picture of the process.
For anyone uncertain about injections entirely, it is worth knowing that other licensed options exist that do not involve a needle at all, including the recently approved oral semaglutide tablet. Those also require a consultation, for the same reasons.
The short version: find a pharmacy on the GPhC register, complete a proper clinical assessment, and let a prescriber decide whether treatment is appropriate for you. Cost is a reasonable thing to think about, private weight loss treatment is a meaningful outlay, and our treatment page sets out what is included in a single transparent price. Consultation, prescription, delivery and aftercare are all part of it, with no subscription and no auto-renewal. Every repeat order goes through a fresh clinical review.
If you want to understand more about what the injection process involves before committing to anything, our guide to the consultation process walks through each stage. And if side effects are a concern (a fair thing to think about before starting) this page covers the evidence on tolerability across available options. The right time for the consultation CTA is after you feel genuinely informed. So: when you are ready to speak to a prescriber, start your free consultation and a clinician will review your details the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.